NF-kB Inhibitors - 2018 Pipeline Insights with Analysis by Development Stage, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “NF-kB Inhibitors- Pipeline Insights, 2018” report has been added to ResearchAndMarkets.com’s offering.
This report outlays comprehensive insights of present scenario and growth prospects across NF-kB Inhibitors.
A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.
This report provides detailed analysis of 12+ active products with more than 10 companies involved. Some of the key players include AMG0101 of AnGes MG and Bardoxolone methyl of Reata Pharmaceuticals, and BIIB098 of Alkermes/Biogen.
Products covered by PhasePhase III, Phase II, Phase I Pre-clinical Inactive (Dormant and Discontinued)
Overview of pipeline development activities for NF-kB InhibitorsPipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Therapeutic segmentation of products for NF-kB Inhibitors. The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
ScopeProvides an overview of therapeutic pipeline activity for NF-kB Inhibitors across the complete product development cycle including all clinical and non-clinical stages It comprises of detailed profiles of NF-kB Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across NF-kB Inhibitors
Key Topics CoveredExecutive Summary Overview Introduction Structure Mechanism of Action Inducers Repressors Clinical Significance NF-kB Inhibitors Pipeline Therapeutics (Active Products) Pipeline Therapeutics (Inactive Products) Comparative Analysis Late Stage Products (Phase III) Comparative Analysis AMG0101: AnGes MG Product Description Research and Development Product Development Activities The list continues. Mid Stage Products (Phase II) Comparative Analysis CPI-0610: CONSTELLATION Product Description Research and Development Product Development Activities The list continues. Early Stage Products (Phase I) Comparative Analysis Pre-clinical Stage Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Inactive Products (Dormant & Discontinued Products) Comparative Analysis Appendix
Companies FeaturedAnGes MG Catabasis Pharmaceuticals Constellation Dendright Incuron MedDay Pharmaceutical Neurmedix Realm Therapeutics Reata Pharmaceuticals Tracon Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/jn49nn/nfkb_inhibitors?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005617/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/30/2018 01:01 PM/DISC: 07/30/2018 01:01 PM